Pirfenidone, a novel anti-fibrotic agent, provides higher benefit for idiopathic pulmonary fibrosis (IPF) patients with better pulmonary function

被引：0
作者：
Ebina, M.
Kimura, Y.
Ohta, H.
Hisata, S.
Tamada, T.
Nukiwa, T.
机构：
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2010年 / 181卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3988
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Factors Affecting The Selection Of Anti-Fibrotic Therapy For Idiopathic Pulmonary Fibrosis
    Kaur, R.
    King, C.
    Brown, A.
    Ahmad, S.
    Shlobin, O. A.
    Weir, N.
    Nathan, S. D.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [22] A review of Idiopathic Pulmonary Fibrosis patients on anti-fibrotic treatment in the mid west area
    Ryan, N.
    Ryan, P.
    Gleeson, E.
    Cullinan, M.
    Mcinerney, C.
    Casserly, B.
    O'Brien, A.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2017, 186 (SUPPL 10) : S441 - S442
  • [23] Anti-fibrotic role of inhaled interferon-γ in idiopathic pulmonary fibrosis
    Hasaneen, Nadia
    Tuong Vu
    Fusiak, Timothy
    Foda, Hussein
    Condos, Rany
    Smaldone, Gerald
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [24] Newer developments in idiopathic pulmonary fibrosis in the era of anti-fibrotic medications
    Nair, Girish B.
    Matela, Ajsza
    Kurbanov, Daniel
    Raghu, Ganesh
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2016, 10 (06) : 699 - 711
  • [25] Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
    Noble, Paul
    Albera, Carlo
    Kirchgaessler, Klaus-Uwe
    Gilberg, Frank
    Petzinger, Ute
    Costabel, Ulrich
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [26] Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF)
    Takaiwa, Takuya
    Tachibana, Hiromasa
    Arita, Machiko
    Ishida, Tadashi
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [27] Pirfenidone Is Efficacious In Patients With Idiopathic Pulmonary Fibrosis (ipf) And Mild Restrictive Disease
    Albera, C.
    Bradford, W. Z.
    Costabel, U.
    Fagan, E. A.
    Glaspole, I.
    Glassberg, M. K.
    Gorina, E.
    Kardatzke, D.
    King, T. E.
    Lancaster, L.
    Lederer, D. J.
    Nathan, S. D.
    Pereira, C.
    Spirig, D.
    Swigris, J. J.
    Valeyre, D.
    Noble, P. W.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [28] Safety of Combined Pirfenidone and Nintedanib in Subgroups of Patients with Idiopathic Pulmonary Fibrosis (IPF)
    Flaherty, K.
    Fell, C. D.
    Huggins, J. T.
    Nunes, H.
    Sussman, R.
    Valenzuela, C.
    Petzinger, U.
    Stauffer, J. L.
    Gilberg, F.
    Bengus, M.
    Wijsenbeek, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
  • [29] Long term efficacy of pirfenidone therapy in patients with idiopathic pulmonary fibrosis (IPF)
    Takaiwa, Takuya
    Tachibana, Hiromasa
    Arita, Machiko
    Ishida, Tadashi
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [30] Factors influencing Idiopathic Pulmonary Fibrosis (IPF) anti-fibrotic decisions in a single UK centre; patient and physician perspectives
    Papadopoulos, Alexis
    Zannetos, Savvas
    Hoyles, Rachel
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
12345